BR112012014235A2 - tiazóis bicíclicos como moduladores alostéricos de receptores mglur5 - Google Patents
tiazóis bicíclicos como moduladores alostéricos de receptores mglur5Info
- Publication number
- BR112012014235A2 BR112012014235A2 BR112012014235A BR112012014235A BR112012014235A2 BR 112012014235 A2 BR112012014235 A2 BR 112012014235A2 BR 112012014235 A BR112012014235 A BR 112012014235A BR 112012014235 A BR112012014235 A BR 112012014235A BR 112012014235 A2 BR112012014235 A2 BR 112012014235A2
- Authority
- BR
- Brazil
- Prior art keywords
- mglur5
- allosteric
- receptor modulators
- compounds
- bicyclic thiazoles
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
tiazóis bicíclicos como moduladores alostéricos de receptores mglur5. a presente invenção refere-se a novos tiazóis bicíclicos que são moduladores alostéricos positivos do receptor metabotrópico de glutamato subtipo 5 ("mglur5") e úteis para o tratamento ou a prevenção de transtornos associados com disfunção do glutamato e de doenças nas quais o subtipo mglur5 de receptores está envolvido. adicionalmente, a invenção é direcionada a composições farmacêuticas compreendendo tais compostos, a processos para preparar tais compostos e composições e ao uso de tais compostos e composições para a prevenção e o tratamento de transtornos nos quais mglur5 está envolvido.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09179850 | 2009-12-18 | ||
PCT/EP2010/069972 WO2011073347A1 (en) | 2009-12-18 | 2010-12-16 | Bicyclic thiazoles as allosteric modulators of mglur5 receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012014235A2 true BR112012014235A2 (pt) | 2016-06-14 |
Family
ID=42112312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012014235A BR112012014235A2 (pt) | 2009-12-18 | 2010-12-16 | tiazóis bicíclicos como moduladores alostéricos de receptores mglur5 |
Country Status (18)
Country | Link |
---|---|
US (1) | US9174953B2 (pt) |
EP (1) | EP2513118B1 (pt) |
JP (1) | JP5763673B2 (pt) |
KR (1) | KR20120101551A (pt) |
CN (1) | CN102666551B (pt) |
AU (1) | AU2010332819B2 (pt) |
BR (1) | BR112012014235A2 (pt) |
CA (1) | CA2782947A1 (pt) |
CL (1) | CL2012001606A1 (pt) |
CO (1) | CO6541592A2 (pt) |
EA (1) | EA020010B1 (pt) |
ES (1) | ES2437166T3 (pt) |
IL (1) | IL220361A0 (pt) |
MX (1) | MX2012007005A (pt) |
NZ (1) | NZ600603A (pt) |
SG (1) | SG181715A1 (pt) |
WO (1) | WO2011073347A1 (pt) |
ZA (1) | ZA201204435B (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130252943A1 (en) * | 2012-02-29 | 2013-09-26 | Vanderbilt University | Bicyclic oxazole lactams as allosteric modulators of mglur5 receptors |
PL3096790T3 (pl) | 2014-01-21 | 2020-01-31 | Janssen Pharmaceutica, N.V. | Kombinacje zawierające pozytywne modulatory allosteryczne lub agonistów ortosterycznych metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie |
ME03518B (me) | 2014-01-21 | 2020-04-20 | Janssen Pharmaceutica Nv | Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena |
CN104262181A (zh) * | 2014-05-14 | 2015-01-07 | 上海应用技术学院 | 一种含氟基团的3-(苯基-1-亚胺)丙酸乙酯类似物的制备方法 |
US10918632B2 (en) | 2016-09-07 | 2021-02-16 | The Children's Hospital Of Philadelphia | Nonselective metabotropic glutamate receptor activators for treatment of anorexia nervosa and binge eating disorder |
CN109942600B (zh) * | 2019-04-15 | 2021-08-20 | 内蒙古京东药业有限公司 | 一种依度沙班的制备方法 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2873378B2 (ja) | 1989-08-03 | 1999-03-24 | 株式会社トーキン | 有リード型チップコイル |
DE59106349D1 (de) * | 1990-06-23 | 1995-10-05 | Basf Ag | Dicarbonsäureimide als Herbizide. |
US5753664A (en) | 1995-03-16 | 1998-05-19 | Takeda Chemical Industries, Ltd. | Heterocyclic compounds, their production and use |
JP2000108513A (ja) | 1998-10-05 | 2000-04-18 | Mitsui Chemicals Inc | 光記録媒体 |
JP2002105085A (ja) | 2000-09-28 | 2002-04-10 | Yamanouchi Pharmaceut Co Ltd | 新規イミダゾチアゾール誘導体 |
US20070060618A1 (en) * | 2002-10-24 | 2007-03-15 | Merck & Co., Inc. | Alkyne derivatives as tracers for metabotropic glutamate receptor binding |
TWI301760B (en) | 2004-02-27 | 2008-10-11 | Merz Pharma Gmbh & Co Kgaa | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors |
ATE446962T1 (de) | 2004-12-17 | 2009-11-15 | Lilly Co Eli | Thiazolopyridinon-derivate als mch- rezeptorantagonisten |
RU2007125622A (ru) | 2005-01-14 | 2009-02-20 | Ф. Хоффманн-Ля Рош Аг (Ch) | Производные тиазол-4-карбоксамида в качестве антагонистов mclur5 |
EP1910350A1 (en) | 2005-07-09 | 2008-04-16 | AstraZeneca AB | 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes |
WO2007023242A1 (en) * | 2005-08-24 | 2007-03-01 | Merz Pharma Gmbh & Co. Kgaa | Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors |
EP1945620A2 (en) | 2005-11-07 | 2008-07-23 | Irm Llc | Compounds and compositions as ppar modulators |
BRPI0618636A2 (pt) * | 2005-11-08 | 2011-09-06 | Hoffmann La Roche | derivados de tiazolo [4,5-c]piridina |
DE102006011574A1 (de) | 2006-03-10 | 2007-10-31 | Grünenthal GmbH | Substituierte Imidazo[2,1-b]thiazol-Verbindungen und ihre Verwendung zur Herstellung von Arzneimitteln |
WO2008001076A1 (en) | 2006-06-26 | 2008-01-03 | Ucb Pharma S.A. | Fused thiazole derivatives as kinase inhibitors |
EP2049548A1 (en) | 2006-07-27 | 2009-04-22 | UCB Pharma, S.A. | Fused oxazoles & thiazoles as histamine h3- receptor ligands |
GB0622202D0 (en) | 2006-11-07 | 2006-12-20 | Addex Pharmaceuticals Sa | Novel compounds |
EP2094712B1 (en) | 2006-11-15 | 2011-10-12 | Vertex Pharmceuticals Incorporated | Compounds useful as protein kinase inhibitors |
JP4714669B2 (ja) | 2006-12-01 | 2011-06-29 | 日本化薬株式会社 | ヘッダーアッシー、スクイブならびにエアバッグ用ガス発生装置およびシートベルトプリテンショナー用ガス発生装置 |
ES2392276T3 (es) | 2006-12-14 | 2012-12-07 | Eli Lilly & Company | Derivados de 5-[4-(azetidin-3-iloxi)-fenil]-2-fenil-5H-tiazolo[5,4-c]piridin-4-ona y su uso como antagonistas del receptor de MCH |
MX2009013169A (es) | 2007-06-03 | 2010-04-30 | Univ Vanderbilt | Moduladores alostericos positivos del mglur5 benzamida y metodos de elaboracion y uso de los mismos. |
JP2011507910A (ja) | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
EP2414340A1 (en) | 2009-04-03 | 2012-02-08 | Dainippon Sumitomo Pharma Co., Ltd. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
CA2784646A1 (en) | 2009-12-18 | 2011-06-23 | Boehringer Ingelheim International Gmbh | Hcv combination therapy |
KR20120097400A (ko) | 2009-12-18 | 2012-09-03 | 얀센 파마슈티카 엔.브이. | Mglur5 리셉터의 알로스테릭 조절자로서의 비사이클릭 티아졸 |
-
2010
- 2010-12-16 CN CN201080057656.7A patent/CN102666551B/zh not_active Expired - Fee Related
- 2010-12-16 KR KR1020127018643A patent/KR20120101551A/ko not_active Application Discontinuation
- 2010-12-16 EA EA201290534A patent/EA020010B1/ru not_active IP Right Cessation
- 2010-12-16 MX MX2012007005A patent/MX2012007005A/es active IP Right Grant
- 2010-12-16 CA CA2782947A patent/CA2782947A1/en not_active Abandoned
- 2010-12-16 JP JP2012543767A patent/JP5763673B2/ja not_active Expired - Fee Related
- 2010-12-16 ES ES10790989.7T patent/ES2437166T3/es active Active
- 2010-12-16 BR BR112012014235A patent/BR112012014235A2/pt not_active IP Right Cessation
- 2010-12-16 EP EP10790989.7A patent/EP2513118B1/en active Active
- 2010-12-16 SG SG2012044053A patent/SG181715A1/en unknown
- 2010-12-16 WO PCT/EP2010/069972 patent/WO2011073347A1/en active Application Filing
- 2010-12-16 NZ NZ600603A patent/NZ600603A/xx not_active IP Right Cessation
- 2010-12-16 AU AU2010332819A patent/AU2010332819B2/en not_active Ceased
- 2010-12-16 US US13/516,968 patent/US9174953B2/en not_active Expired - Fee Related
-
2012
- 2012-06-13 IL IL220361A patent/IL220361A0/en unknown
- 2012-06-14 CL CL2012001606A patent/CL2012001606A1/es unknown
- 2012-06-15 CO CO12101576A patent/CO6541592A2/es unknown
- 2012-06-15 ZA ZA2012/04435A patent/ZA201204435B/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP5763673B2 (ja) | 2015-08-12 |
AU2010332819A1 (en) | 2012-06-21 |
ES2437166T3 (es) | 2014-01-09 |
CN102666551B (zh) | 2014-12-10 |
CN102666551A (zh) | 2012-09-12 |
CO6541592A2 (es) | 2012-10-16 |
MX2012007005A (es) | 2012-07-03 |
KR20120101551A (ko) | 2012-09-13 |
ZA201204435B (en) | 2014-11-26 |
CA2782947A1 (en) | 2011-06-23 |
US20120252800A1 (en) | 2012-10-04 |
IL220361A0 (en) | 2012-08-30 |
SG181715A1 (en) | 2012-07-30 |
EP2513118B1 (en) | 2013-09-18 |
EA201290534A1 (ru) | 2012-11-30 |
NZ600603A (en) | 2013-07-26 |
WO2011073347A1 (en) | 2011-06-23 |
JP2013514327A (ja) | 2013-04-25 |
CL2012001606A1 (es) | 2012-10-05 |
EA020010B1 (ru) | 2014-07-30 |
US9174953B2 (en) | 2015-11-03 |
AU2010332819B2 (en) | 2014-02-27 |
EP2513118A1 (en) | 2012-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015031903A8 (pt) | composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto | |
BR112012007102A2 (pt) | compostos policíclicos como antagonistas de receptores do ácido lisofosfatpidico | |
BR112013011448B8 (pt) | Composto, composição farnmacêutica, e, uso do composto | |
MX2011005242A (es) | Derivados de indol y benzoxazina como moduladores de los receptores de glutamato metabotropicos. | |
BR112012020273A2 (pt) | Compostos de pirazolopiridina, pirazolopirazina, pirazolopirimidina, pirazolotiofeno e pirazolotiazol como pontencializadores alostéricos de mglur4, composições e métodos de tratamento de disfunção neurológica | |
BRPI1012870B8 (pt) | derivados de 1,2,4-triazolo[4,3-a]piridina e seu uso como moduladores alostericos positivos de receptores de mglur2 e composição farmacêutica | |
BRPI0919876A8 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para intensificar a qualidade do sono, para tratar insônia, e para tratar ou controlar obesidade em um paciente mamífero que necessita do mesmo. | |
CL2008002744A1 (es) | Compuestos derivados de 1,3-disustituidos-4-fenil-1h-piridin-2-ona, moduladores alostericos del receptor glutamatérgico mglur2; composición farmacéutica y uso de los compuestos en el tratamiento de afecciones neurológicas y siquiatricas mediadas por mglur2. | |
BRPI0719361B8 (pt) | composto, composição farmacêutica, e, uso do composto | |
BR112012013431A8 (pt) | composto, composição farmacêutica e seu uso | |
CR10309A (es) | "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1" | |
MY163055A (en) | Polycyclic antagonists of lysophosphatidic acid receptors | |
BR112015030595A2 (pt) | moduladores de receptor de estrogênio de azetidina e usos dos mesmos | |
CL2007001885A1 (es) | Compuestos derivados de urea de tropano, moduladores de la actividad de la 11betahsd1; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como obesidad, diabetes, hipertension, aterosclerosis, demencia y osteoporosis. | |
BR112013006395A2 (pt) | moduladores do receptor de estrogênio e seus usos. | |
BR112015022566A2 (pt) | composto e composição farmacêutica | |
BR112015026721A2 (pt) | derivados de 3-(2-aminopirimidin-4-il)-5-(3-hidroxipropinil)-1h-pirrolo[2,3-c]piridina como inibidores de nik para o tratamento de câncer | |
UY30572A1 (es) | N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2 | |
JO3368B1 (ar) | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 | |
BR112012014235A2 (pt) | tiazóis bicíclicos como moduladores alostéricos de receptores mglur5 | |
BR112017001726A2 (pt) | compostos de 6,7-di-hidropirazolo [1,5-a]pirazin-4(5h)-ona e seus usos como moduladores alostéricos negativos de receptores mglur2 | |
ATE542795T1 (de) | Benzylpiperazinderivate als motilin- rezeptorantagonisten | |
BR112017001998A2 (pt) | compostos 6,7-di-hidropirazolo[1,5-a]pirazin-4(5h)-ona e seu uso como moduladores alostéricos negativos de receptores mglur2 | |
PL2201002T3 (pl) | Antagoniści receptora 5-HT7 | |
PH12016500312A1 (en) | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |